These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11881595)

  • 1. FDA approves first biologic treatment for sepsis.
    FDA Consum; 2002; 36(1):3. PubMed ID: 11881595
    [No Abstract]   [Full Text] [Related]  

  • 2. Kigris. FDA approves first biologic for sepsis.
    Nursing; 2002 Feb; 32(2):18. PubMed ID: 11924158
    [No Abstract]   [Full Text] [Related]  

  • 3. Activated protein C for severe sepsis.
    Ely EW; Bernard GR; Vincent JL
    N Engl J Med; 2002 Sep; 347(13):1035-6. PubMed ID: 12324564
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hemorrhagic risk of drotrecogin alfa (activated) in severe sepsis].
    Perrotin D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():16-9. PubMed ID: 15359934
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinant human activated protein C for severe sepsis.
    Kapur S; Kupfer Y; Tessler S
    N Engl J Med; 2001 Jul; 345(3):219-20; author reply 220-1. PubMed ID: 11463021
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessing the use of activated protein C in the treatment of severe sepsis.
    Siegel JP
    N Engl J Med; 2002 Sep; 347(13):1030-4. PubMed ID: 12324563
    [No Abstract]   [Full Text] [Related]  

  • 7. Breakthrough found in treatment of severe sepsis.
    Clin Resour Manag; 2001 Jul; 2(7):107-9. PubMed ID: 11482248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA approves first biologic treatment for sepsis.
    Dent Today; 2002 Mar; 21(3):28, 30. PubMed ID: 11915215
    [No Abstract]   [Full Text] [Related]  

  • 9. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe sepsis and therapy with activated protein C.
    Parrillo JE
    N Engl J Med; 2005 Sep; 353(13):1398-400. PubMed ID: 16192486
    [No Abstract]   [Full Text] [Related]  

  • 11. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The FDA's questions].
    Opal S
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():20-2. PubMed ID: 15359935
    [No Abstract]   [Full Text] [Related]  

  • 13. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
    Eichacker PQ; Danner RL; Suffredini AF; Cui X; Natanson C
    Crit Care Med; 2005 Oct; 33(10):2426-8. PubMed ID: 16215410
    [No Abstract]   [Full Text] [Related]  

  • 14. Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.
    Eichacker PQ; Natanson C; Danner RL
    N Engl J Med; 2006 Oct; 355(16):1640-2. PubMed ID: 17050887
    [No Abstract]   [Full Text] [Related]  

  • 15. From the Food and Drug Administration.
    Schwetz BA
    JAMA; 2002 Jan; 287(1):33. PubMed ID: 11754690
    [No Abstract]   [Full Text] [Related]  

  • 16. Conclusions: drotrecogin alfa (activated)--from bench to practical use at the bedside.
    Maki DG
    Am J Surg; 2002 Dec; 184(6A Suppl):S47-50. PubMed ID: 12521617
    [No Abstract]   [Full Text] [Related]  

  • 17. Protein C may be sepsis solution.
    Garber K
    Nat Biotechnol; 2000 Sep; 18(9):917-8. PubMed ID: 10973198
    [No Abstract]   [Full Text] [Related]  

  • 18. [Activated protein C--recent addition to therapy of sepsis].
    Gårdlund B; Sjölin J
    Lakartidningen; 2003 Jun; 100(26-27):2292-6. PubMed ID: 12872375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioethics, the Surviving Sepsis Campaign and the industry.
    Bion J; Vincent JL; Angood P
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):63. PubMed ID: 16489529
    [No Abstract]   [Full Text] [Related]  

  • 20. Bioethics, the Surviving Sepsis Campaign, and the industry.
    Wiedermann CJ
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):442-4. PubMed ID: 16091869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.